Common Data Model-based Analysis of Selective Leukoreduction Protocol Compliance at Three Hospitals

Abstract

Background: The selective leukoreduction protocol (SLP) is limited in that patients who require it can be overlooked. We estimated SLP compliance (SLPC) using the Observational Medical Outcomes Partnership common data model (CDM).Methods: Patients were classified into eight groups: pre-and post-hematology disease (A and B), pre-and post-solid organ transplantation (C and D), solid cancer (E), immunodeficiency (F), anticancer therapy (G), and cardiovascular surgery (H). We examined the red blood cell (RBC) transfusion history from three hospital datasets comprising approximately three million patients over 20 years using CDM-based analysis. SLPC was calculated as the percentage of patients who received only leukoreduced RBCs in total patients transfused RBCs.Results: In total, 166,641 patients from three hospitals were enrolled in this study. From 2001 to 2021, SLPC in all groups, except H, tended to increase, although there were differences among the hospitals. Based on the most recent values (2017-2021), the SLPC in groups A, B, D, and G was maintained at ≥ 75% until 1,095 days before or after diagnosis or treatment. Groups E, F, and H had < 50% SLPC one day after diagnosis and treatment.Conclusions: CDM analysis supports the review of large datasets for SLPC evaluation. Although SLPC tended to improve in most patient groups, additional education and monitoring are needed for groups that continue to show low SLPC.

Adverse Events Associated with the Use of Leukocyte Reduction Filters and Blood Transfusion Sets: Experience of a Single Institute in Korea and Status of Adverse Event Reporting in Korea and the United States

“…백혈구제거필터는 HLA 동종면역, 혈소판수혈 불응증, CMV 감염 전파 및 발열성비용혈수혈이 상반응을 방지하기 위해 사용되는 의료기기로 [2], 수혈관련 저혈압반응과의 연관성이 있다고 알려 져 있다 [3]. 저장혈액 내 혈구 또는 섬유소 응괴를 제거하기 위한 수혈세트도 빈번하게 사용되는 의 료기기이다.…”